About This Publication:

  • Print This Page
  • Subscribe to an RSS Feed

Sample Content 

LOGIN
My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Human Gene Therapy

Editor-in-Chief: James M. Wilson, MD, PhD
Deputy Editor: George Dickson, BSc, PhD
Human Gene Therapy Editor: Mark A. Kay, MD, PhD
Methods Editor: Thierry VandenDriessche, PhD
Clinical Development Editor: Barry J. Byrne, MD, PhD

ISSN: 1043-0342 • Published 22 issues annually • Online ISSN: 1557-7422

Current Volume: 25

Latest Impact Factor* is 3.623

*2013 Journal Citation Reports® published by Thomson Reuters, 2014

Featured Media

Human Gene Therapy Celebrates 25 Years!

A Video Message from James M. Wilson

In a brand new video message, James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, shares exciting news about the Journal's 25th Anniversary and how you can get involved in the celebration!

 



Winners of the 12 Pioneer Awards for Seminal Work in Gene and Cell Therapy

Interview Series by Editor-in-Chief James M. Wilson


Interview between Editor-in-Chief James M. Wilson, MD, PhD and Pioneer winner Ron Crystal, MD on his “eureka” moment and views on the future of the field. Dr. Crystal's Perspective can be found here.

Ronald G. Crystal, MD, Weill Cornell Medical College, Cornell University
Nominated for: Adenoviral vectors/role in translation of gene therapy to clinic



GEN interviews Dr. James Wilson

Dr. James Wilson is a professor in the department of pathology and laboratory medicine, and the director of the gene therapy program, at the University of Pennsylvania. He is also the editor of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. During this interview with GEN, Dr. Wilson discusses his concept of a disruptive technology and explains why he believes gene therapy falls into this category. In addition to this SKYPE interview, Dr. Wilson further elaborated on his view of gene therapy as a disruptive technology in a column in the January 2012 issue of Human Gene Therapy which can be viewed here.

Human Gene Therapy Podcast Series


Dr. James Wilson

Dr. James Wilson, Editor of Human Gene Therapy interviews leading members in the field of gene therapy including Andrew Baker & Lynda Coughlan from the University of Glasgow, Luigi Naldini from the San Raffaele Telethon Institute for Gene Therapy, Thierry VandenDriessche from the Free University of Brussels & the University of Leuven in Belgium, and Seppo Yla-Herttuala of ESGCT.

*Audio plays in a popup window. Please make sure your popup blocker is off.

Terence Flotte Dr. Terence R. Flotte, Dean of University of Massachusetts Medical School, discusses the role of gene and cell therapy in the era of health care reform. Featured commentary from Dr. Flotte, and co-author Walter H. Ettinger, on the topic is available here.
LISTEN NOW!*

Thierry VandenDriessche Thierry VandenDriessche, Professor in Medicine for the Free University of Brussels and the University of Leuven in Belgium, discusses the use of vector AAV to treat patients with hemophilia B.
LISTEN NOW!*

Andrew Baker Andrew Baker discusses his approach of targeting vectors to endothelial cells of vascular grafts, among other newsworthy topics.
LISTEN NOW!*

Lynda CoughlanLynda Coughlan, Research Associate at the University of Glasgow and an advocate for early-career researchers to the British Society for Gene Therapy, has organized a workshop to be held at the ESGCT conference on "Careers in Science." She describes what the session will hold.
LISTEN NOW!*

Luigi NaldiniLuigi Naldini, the Scientific Director for the San Raffaele Telethon Institute for Gene Therapy in Milano, Italy, discusses the progress, benefits, and possible challenges of ex vivo lentiviral gene transfer techniques.
LISTEN NOW!*

Thierry VandenDriesscheThierry VandenDriessche, Professor in Medicine for the Free University of Brussels and the University of Leuven in Belgium, discusses the great advancements made in the clinical development of gene therapy in European countries.
LISTEN NOW!*

Seppo Yla-HerttualaSeppo Yla-Herttuala, President of the ESGCT, discusses the expanding field of cell and gene therapy—from important advances to upcoming challenges—as well as updates from his own current research.
LISTEN NOW!*

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    Tissue Engineering, Parts A, B, & C

    Tissue Engineering, Parts A, B, & C

    The preeminent, biomedical journal bringing together the principles of engineering and life sciences to advance the field with cutting-edge research and applications on all aspects of tissue growth and regeneration.

    Nucleic Acid Therapeutics

    Nucleic Acid Therapeutics

    formerly Oligonucleotides

    Focuses on cutting-edge research and applications to find and examine new approaches using nucleic acids in therapeutics including oligonucleotides, gene modification, aptamers, RNA nanoparticles, ribozymes, and more.

    Stem Cells and Development

    Stem Cells and Development

    Globally recognized as the trusted source for critical, even controversial coverage of emerging hypotheses and novel findings on stem cells of all tissue types and their potential therapeutic applications.

    Zebrafish

    Zebrafish

    Solely focused on disseminating the latest cutting-edge advances in the zebrafish as a model organism for the study of vertebrate development, with attention to other aquarium species including medaka, Fugu, and Xiphophorus.

Browse All Publications »